双歧杆菌三联活菌联合mFOLFOX6方案对结直肠癌术后患者肠道菌群的影响  

Effect of Bifidobacteria Triple Live Bacteria Combined with mFOLFOX6 Regimen on Postoperative Intestinal Flora in Patients with Colorectal Cancer

作　　者：张振 李中辉 ZHANG Zhen;LI Zhonghui(Department of General Internal Medicine,Yicheng District People’s Hospital,Zaozhuang 277000,China)

机构地区：[1]山东省枣庄市峄城区人民医院综合内科,山东枣庄277000

出　　处：《中国伤残医学》2024年第21期31-34,49,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:分析双歧杆菌三联活菌联合mFOLFOX6方案对结直肠癌(CC)术后患者的影响。方法:选取2018年6月—2023年6月枣庄市峄城区人民医院收治的110例CC术后患者为研究对象,按随机数字表法将其分为对照组与研究组,各55例。对照组采用mFOLFOX6方案治疗,研究组在对照组基础上联合双歧杆菌三联活菌治疗,两组均治疗6个月。比较两组肠道菌群水平、免疫功能指标、炎症因子水平及不良反应发生情况。结果:治疗后,两组乳酸杆菌、双歧杆菌、粪肠球菌数目均高于治疗前,大肠杆菌数目低于治疗前,且研究组乳酸杆菌为(7.64±1.23)IgCFU/g、双歧杆菌为(9.85±2.04)IgCFU/g、粪肠球菌为(8.52±1.87)IgCFU/g,高于对照组的(6.70±0.87)IgCFU/g、(8.14±1.75)IgCFU/g、(7.01±1.33)IgCFU/g,大肠杆菌为(8.25±1.01)IgCFU/g,低于对照组的(9.68±1.34)IgCFU/g,差异均有统计学意义(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)均高于治疗前,CD8^(+)低于治疗前,研究组CD3^(+)为(42.38±3.68)%、CD4^(+)为(36.78±4.11)%,均高于对照组的(37.49±3.01)%、(31.59±3.45)%,CD8^(+)为(19.72±2.30)%,低于对照组的(23.48±2.59)%,差异均有统计学意义(P<0.05)。治疗后,两组炎症因子水平均低于治疗前,且研究组C反应蛋白、白细胞介素-6、肿瘤坏死因子-α水平分别为(9.45±1.01)mg/L、(76.54±14.36)pg/mL、(14.37±1.58)pg/mL,均低于对照组的(12.36±1.57)mg/L、(87.42±19.75)pg/mL、(22.69±2.15)pg/mL,差异均有统计学意义(P<0.05)。研究组的不良反应发生率为10.91%,相较于对照组的16.36%,差异无统计学意义(P>0.05)。结论:双歧杆菌三联活菌联合mFOLFOX6方案可调节CC术后患者肠道菌群,增强免疫功能,控制炎症反应,具有一定的安全性。Objective:To analyze the effect of bifidobacteria triple live bacteria combined with mFOLFOX6 regimen on postoperative patients with colorectal cancer(CC).Methods:A total of 110 CC postoperative patients admitted to Yicheng District People’s Hospital from June 2018 to June 2023 were selected and divided into a control group and a study group according to random number table method,with 55 cases in each group.The control group was treated with mFOLFOX6 regimen,and the study group was treated with bifidobacterium triple live bacteria on the basis of the control group.Both groups were treated for 6 months.The levels of intestinal flora,immune function indexes,inflammatory factors and adverse reactions were compared between the two groups.Result:After treatment,the numbers of lactobacillus,bifidobacterium and Enterococcus faecalis in both groups were higher than before treatment,while the numbers of Escherichia coli were lower than before treatment,and in the study group,the numbers of Lactobacillus,bifidobacterium and Enterococcus faecalis were(7.64±1.23)IgCFU/g,(9.85±2.04)IgCFU/g,and(8.52±1.87)IgCFU/g,which were higher than(6.70±0.87)IgCFU/g,(8.14±1.75)IgCFU/g,(7.01±1.33)IgCFU/g than control group,escherichia coli was(8.25±1.01)IgCFU/g,which was lower than control group(9.68±1.34)IgCFU/g,the differences were statistically significant(P<0.05).After treatment,CD3^(+)and CD4^(+)in both groups were higher than before treatment,CD8^(+)was lower than before treatment,and in the study group,CD3^(+)and CD4^(+)were(42.38±3.68)%and(36.78±4.11)%respectively,which were higher than those in the control group(37.49±3.01)%and(31.59±3.45)%respectively,CD8^(+)was(19.72±2.30)%,which was lower than(23.48±2.59)%in the control group,the difference were statistically significant(P<0.05).After treatment,the levels of inflammatory factors in the two groups were lower than before treatment,and the levels of C-reactive protein,interleukin-6,tumor necrosis factor-αin the study group were(9.45±1.01)mg/L,(76.54±14.36)pg/mL,a

关 键 词：结直肠癌 肠道菌群 免疫功能 不良反应 

分 类 号：R735[医药卫生—肿瘤]